HC Wainwright Predicts Urogen Pharma Q1 Earnings

Key Points

• HC Wainwright forecasts UroGen Pharma (URGN) will report a Q1 2027 loss of ($0.28) per share, while the consensus full‑year estimate is a ($1.45) per share loss; the firm also projects Q2 ($0.04) and Q4 $0.51 EPS.
• In its most recent quarter UroGen reported EPS of ($0.54), beating the consensus of ($0.66) by $0.12, while revenue came in at $37.84 million versus estimates of $39.92 million.
• Analyst views are mixed but generally positive: the MarketBeat consensus rating is a “Moderate Buy” with a $34.13 average price target, ranging from sell to strong‑buy among brokers.

Urogen Pharma (NASDAQ:URGN - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Urogen Pharma in a report issued on Thursday, April 23rd. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.28) per share for the quarter. The consensus estimate for Urogen Pharma's current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Urogen Pharma's Q2 2027 earnings at ($0.04) EPS and Q4 2027 earnings at $0.51 EPS.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.12. The company had revenue of $37.84 million during the quarter, compared to analyst estimates of $39.92 million.

Several other brokerages have also recently weighed in on URGN. Weiss Ratings reissued a "sell (d-)" rating on shares of Urogen Pharma in a research note on Monday, April 20th. D. Boral Capital reissued a "buy" rating and issued a $33.00 price target on shares of Urogen Pharma in a research note on Tuesday, March 31st. Oppenheimer reissued an "outperform" rating on shares of Urogen Pharma in a research note on Monday, March 2nd. Finally, Jefferies Financial Group raised Urogen Pharma to a "strong-buy" rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $34.13.

Urogen Pharma Stock Performance

Shares of URGN stock opened at $24.11 on Monday. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -7.53 and a beta of 1.43. The stock has a 50-day moving average of $20.11 and a 200-day moving average of $21.19. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $30.00.

Insider Activity

In related news, insider Mark Schoenberg sold 7,373 shares of the company's stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $145,174.37. Following the sale, the insider owned 144,985 shares in the company, valued at $2,854,754.65. This represents a 4.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Jason Drew Smith sold 7,479 shares of the company's stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $147,261.51. Following the sale, the general counsel owned 51,326 shares in the company, valued at approximately $1,010,608.94. The trade was a 12.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Urogen Pharma

Several institutional investors and hedge funds have recently made changes to their positions in URGN. Osaic Holdings Inc. boosted its position in shares of Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company's stock valued at $50,000 after purchasing an additional 3,070 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company's stock valued at $53,000 after purchasing an additional 486 shares in the last quarter. State of Wyoming bought a new stake in shares of Urogen Pharma during the 3rd quarter valued at about $66,000. Russell Investments Group Ltd. boosted its position in shares of Urogen Pharma by 1,594.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company's stock valued at $66,000 after purchasing an additional 3,125 shares in the last quarter. Finally, Strs Ohio bought a new position in Urogen Pharma in the third quarter worth approximately $76,000. Institutional investors own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.